UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934 (Amendment
No. )
Filed
by
the Registrant þ
Filed
by
a Party other than the Registrant o
Check
the
appropriate box:
|
o
|
|
Preliminary
Proxy Statement
|
|
|
||
|
o
|
|
Confidential,
for Use of the
Commission
Only (as permitted
by
Rule 14a-6(e)(2))
|
|
|
||
|
o
|
|
Definitive
Proxy Statement
|
|
|
||
|
þ
|
|
Definitive
Additional Materials
|
|
|
||
|
o
|
|
Soliciting
Material Pursuant to Section
240.14a-12
|
Targeted
Genetics Corporation
(Name
of Registrant as Specified in Its Charter)
N/A
(Name
of Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
þ
|
|
No
fee required.
|
|||||||
|
|
|||||||||
|
o
|
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
|||||||
|
|
|||||||||
|
(1)
|
Title
of each class of securities to which transaction applies:
_______________________________________________________________________________
|
||||||||
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
||||||||
|
_______________________________________________________________________________
|
|||||||||
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant
to
Exchange Act Rule 0-
11
(set forth the amount on which the filing fee is calculated and state
how
it was determined):
_______________________________________________________________________________
|
||||||||
|
(4)
|
Proposed
maximum aggregate value of transaction:
_______________________________________________________________________________
|
||||||||
|
(5)
|
Total
fee paid:
|
||||||||
|
_______________________________________________________________________________
|
|||||||||
|
o
|
|
Fee
paid previously with preliminary materials.
|
|||||||
|
o
|
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid
previously. Identify the previous filing by registration statement
number,
or the Form or Schedule and the date of its filing.
|
|||||||
|
(1)
|
Amount
Previously Paid:
_______________________________________________________________________________
|
||||||||
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
||||||||
|
_______________________________________________________________________________
|
|||||||||
|
(3)
|
Filing
Party:
|
||||||||
|
(4)
|
Date
Filed: _______
|
||||||||
On
December 26, 2007, Targeted Genetics Corporation, or Targeted Genetics, mailed
the following notice to its shareholders of record as of November 20, 2007
who
had not already returned proxies or voted in connection with the special meeting
of shareholders scheduled to be held by Targeted Genetics on January 11, 2008.
Shareholders of Targeted Genetics are urged to read Targeted Genetics’
definitive proxy statement filed with the Securities and Exchange Commission
on
November 21, 2007, because it contains important information related to the
special meeting.
[Targeted
Genetics Corporation Logo]
URGENT
NOTICE
AS
OF THE DATE OF THIS LETTER,
OUR
PROXY SOLICITOR HAS NOT RECEIVED YOUR VOTE
December
26, 2007
Dear
Targeted Genetics Shareholder,
Please
remember that the Special Meeting of Shareholders of Targeted Genetics is fast
approaching and will be held on January
11, 2008.
At
the
Special Meeting, you are being asked to vote on the following proposals, as
is
more fully described in the proxy statement described below:
1. An
increase in the number of authorized shares of common stock of the Company
from
30,000,000 shares to 45,000,000 shares.
2. An
increase in the number of authorized shares of preferred stock of the Company
from 600,000 shares to 10,000,000 shares.
We
will
also consider any other business as may properly come before the Special Meeting
and any adjournments or postponements thereof.
Your
vote is important. Approval of the proposals requires the affirmative vote
of
the holders of shares representing a majority of the outstanding shares of
our
common stock. Whether
or not you expect to attend the meeting, you are requested to complete, sign
and
date the enclosed proxy voting instruction form as promptly as possible so
that
your shares may be represented at the meeting.
Targeted
Genetics has a filed a definitive proxy statement in connection with the Special
Meeting and has mailed such proxy statement to shareholders. We urge you to
read
the definitive proxy statement because it contains important information related
to the Special Meeting. The definitive proxy statement can be obtained free
of
charge at the website maintained by the SEC at www.sec.gov.
The
definitive proxy statement may also be obtained free of charge by contacting
Mellon Investor Services at the number that is listed below.
Your
prompt response is appreciated. Given the short time frame before the meeting
date, you are encouraged to vote your shares by utilizing the toll-free number
that is listed below.
We
hope
to hear from you. If you need assistance in casting your vote, please call
Mellon Investor Services (the company’s proxy solicitation agent) at
800-814-0304.
Sincerely,
H.
Stewart Parker
President
and Chief Executive Officer